|
Balance Sheet Cash Flow Statement Hampshire International Business Park, Chineham Basingstoke, Hampshire RG24 8EP, United Kingdom Tel. +44-1256-894-000 Fax +44-1256-894-708 |
Type: Public
On the web:
http://www.shire.com
Employees:
3,769
Employee growth: 9.7%
Shire's drugs help patients pay attention and stay on task. The specialty drug company, the UK's third largest, has a roster that includes attention deficit hyperactivity disorder (ADHD) treatments Vyvanse and Adderall XR. It also makes Pentasa and Lialda, both treatments for ulcerative colitis, as well as drugs for renal diseases and rare genetic disorders like Fabry disease, a genetic disorder. Additional drugs in Shire's portfolio include Carbatrol, a reformulation of a popular epilepsy drug; Alzheimer's disease drug Reminyl; and osteoporosis medication Calcichew. Headquartered in the UK, Shire does most of its business in North America, with sales forces that target specialist physicians.
Key numbers for fiscal year ending December, 2008:
Sales: $3,022.2M
One year growth: 24.0%
Net income: $156.0M
Officers:
Chairman: Matthew W. Emmens
CEO and Director: Angus Russell
CFO and Director: Graham C. Hetherington
Competitors:
Johnson & Johnson
Novartis
UCB
